Data show patients with type 2 diabetes are likelier to reach HbA1c target <7% during 26 weeks’ treatment with Victoza® (liraglutide)
27 November 2012 | By Novo Nordisk
New data analyses...
List view / Grid view
News
Abbott’s HUMIRA® (adalimumab) approved in Europe for severe active pediatric Crohn’s disease
27 November 2012 | By Abbott
Abbott announced that the European Commission has approved HUMIRA®...
European Commission approves Viread®
27 November 2012 | By Gilead Sciences, Inc.
Gilead Sciences announced that the European Commission has granted marketing authorization for two new indications for once-daily Viread®...
Merck and Endocyte announce acceptance for review of European Marketing Authorization applications for vintafolide and companion Diagnostic etarfolatide for folate-receptor positive platinum-resistant ovarian cancer
27 November 2012 | By Merck
Novel personalized treatment approach targets folate receptors on cancer cells...
Gilead announces sustained virologic response rate of 78% from Phase 3 study of sofosbuvir for genotype 2/3 hepatitis C infected patients
27 November 2012 | By Gilead Sciences
Gilead Sciences announced topline results from the Phase 3 POSITRON study...
GSK announces agreement in principle to increase its stake in GlaxoSmithKline Consumer Nigeria PLC
26 November 2012 | By GlaxoSmithKline
GSK and GSK Nigeria have reached agreement...
Novartis receives FDA approval for Flucelvax®, the first cell-culture vaccine in US to help protect against seasonal influenza
20 November 2012 | By Novartis
The US FDA approved the use of Flucelvax®...
GSK supports Coronation Festival event at Buckingham Palace Gardens marking 60 years of innovation and excellence
20 November 2012 | By GlaxoSmithKline
GSK will be a headline partner at the Coronation Festival...
ELIQUIS® (apixaban) approved in Europe for prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation
20 November 2012 | By Bristol-Myers Squibb Company
The EC has approved ELIQUIS®...
Jean-Marc Pardonge appointed as new President of Aptar Pharma Prescription Division
Jean-Marc Pardonge, 52 years old, has been appointed as the new President of Aptar Pharma’s Prescription Division, world leader in the development and manufacturing of nasal and pulmonary drug delivery devices.
Cystic Fibrosis Foundation Therapeutics announces $58 million CF drug discovery agreement with Pfizer
19 November 2012 | By Cystic Fibrosis Foundation
CFFT announced a major expansion of its research collaboration with Pfizer...
FDA approves new indication for PROMACTA® (eltrombopag)
19 November 2012 | By GlaxoSmithKline
GlaxoSmithKline plc announced that the U.S. FDA has approved PROMACTA for the treatment of thrombocytopenia...
Pfizer reports top-line results of a Phase 3 study evaluating pregabalin controlled-release as treatment for patients with fibromyalgia
19 November 2012 | By Pfizer
Top-line results of a Phase 3 study...
Roche study showed that Avastin helped people with newly diagnosed glioblastoma live longer without their disease worsening
17 November 2012 | By Roche
Results from positive phase III AVAglio study...
A LoGiCal® solution for forensic toxicology
16 November 2012 | By kdm communications limited
LGC Standards’ LoGiCal® reference materials are proving a valuable resource for scientists at the Institute of Forensic Research...
